0
0
Thermo Fisher Scientific is strengthening its presence in India as the country’s pharmaceutical and biotechnology sectors increasingly shift toward innovation, advanced research and complex drug development. The US-based life sciences company sees India as one of its fastest-growing markets and expects its customer base in the country to expand significantly over the next five years.
The company’s optimism comes as Indian drugmakers move beyond traditional generics and increasingly invest in biologics, biosimilars, novel therapies and advanced manufacturing. That transformation is creating fresh demand for laboratory equipment, analytical instruments, genetic analysis technologies and other solutions used throughout the drug-development process.
For Thermo Fisher, the trend makes India more than simply a large commercial market. It is becoming an increasingly important research and innovation hub.
Thermo Fisher Sees Strong Growth Opportunity in India
Thermo Fisher expects its customer base in India to grow by around 15% to 20% over the next five years, according to Reuters. The projected expansion is being supported by increasing activity in biopharmaceutical research and manufacturing, as well as demand from sectors such as semiconductors and clean energy.
India is already considered one of Thermo Fisher’s fastest-growing markets in the Asia-Pacific region.
The company expects India to maintain a double-digit growth trajectory, reflecting the increasing sophistication of laboratories and research facilities across the country.
The shift is particularly important for Thermo Fisher because more advanced research requires more sophisticated laboratory infrastructure.
As Indian pharmaceutical companies develop more complex therapies, they need equipment capable of supporting research, testing, quality control and manufacturing at increasingly demanding standards.
Indian Pharma Is Moving Toward Innovation
For decades, India has been widely recognized as a major global supplier of generic medicines.
That position remains important, but the pharmaceutical industry is gradually expanding into areas that require substantially greater research capabilities.
Indian companies are investing more heavily in biosimilars, biologics, specialty medicines and innovative drug development.
This creates an attractive opportunity for companies such as Thermo Fisher.
The more complex a drug becomes, the greater the need for specialized laboratory systems. Drugmakers require technologies that can support everything from early-stage discovery and molecular analysis to clinical development and commercial manufacturing.
Thermo Fisher’s broad portfolio allows it to participate across multiple stages of this process.
Biosimilars Create New Demand for Laboratory Technology
One of the most promising areas is the Indian biosimilars market.
Biosimilars are highly complex biological products that require extensive analytical testing and sophisticated manufacturing processes. Their development therefore creates demand for advanced laboratory technologies.
Thermo Fisher has identified the growing focus on biosimilars as one of the factors supporting its expansion in India.
For Indian pharmaceutical companies, the ability to produce high-quality biosimilars can open opportunities in both domestic and international markets.
For laboratory equipment manufacturers, that means greater demand for technologies that can ensure product consistency, safety and regulatory compliance.
India Is Becoming More Important in Global Drug Research
India’s pharmaceutical industry is also becoming increasingly integrated with global drug-development networks.
International pharmaceutical companies are working with Indian research organizations, contract development and manufacturing organizations, and local drugmakers.
This has created a larger ecosystem of laboratories capable of conducting sophisticated research.
Thermo Fisher sees this expansion as a major opportunity.
The company provides technologies spanning laboratory equipment, analytical instruments, genetic analysis, research consumables, clinical development and biopharmaceutical manufacturing.
Its global portfolio therefore aligns closely with the needs of an industry that is becoming more research-intensive.
More Laboratories Are Targeting Global Standards
Another factor behind Thermo Fisher’s optimism is the growing number of Indian laboratories seeking to meet international standards.
According to Thermo Fisher India and South Asia Managing Director Srinath Venkatesh, the proliferation of laboratories aiming to meet global standards is helping drive demand for the company’s products and solutions.
This is significant because global pharmaceutical production requires strict quality-control systems.
Laboratories must demonstrate that their testing processes are reliable, reproducible and compliant with regulatory requirements.
As Indian companies target more international markets, investments in laboratory infrastructure become increasingly important.
Thermo Fisher Plans to Expand Its Workforce
The company’s growing India business is also expected to translate into additional employment.
Thermo Fisher currently has more than 5,000 employees in India and plans to expand its workforce, particularly in customer-facing positions.
Expanding local teams can help Thermo Fisher respond more quickly to the needs of Indian customers.
It also allows the company to develop deeper relationships with pharmaceutical companies, biotechnology firms, research institutions and other organizations.
For a technology provider operating in a highly specialized market, local expertise can be an important competitive advantage.
India’s Growth Extends Beyond Pharmaceuticals
Although pharmaceuticals and biotechnology are central to the company’s India strategy, Thermo Fisher is also seeing demand from other industries.
The company has identified semiconductors and clean energy among sectors contributing to its growth outlook in India.
These industries increasingly depend on advanced analytical technologies and laboratory testing.
The semiconductor sector, for example, requires precise materials analysis and quality-control processes. Clean-energy technologies similarly depend on research and testing capabilities.
This diversification gives Thermo Fisher another source of potential growth beyond the pharmaceutical industry.
Obesity Drugs Could Become Another Growth Driver
Thermo Fisher is also monitoring the development of India’s growing obesity-drug market.
The expansion of treatments targeting obesity and related metabolic conditions could create additional demand for research and manufacturing technologies.
As pharmaceutical companies develop and produce more advanced therapies, they need reliable laboratory infrastructure throughout the development process.
This gives Thermo Fisher an opportunity to benefit from the growth of new therapeutic categories without having to develop the drugs itself.
Investment Is About More Than Selling Equipment
Thermo Fisher’s strategy in India illustrates how the laboratory equipment industry is changing.
Companies are no longer simply selling individual instruments. They are increasingly providing integrated solutions that support research, clinical development and manufacturing.
At BIO International 2026, Thermo Fisher highlighted new capabilities and strategic investments aimed at helping pharmaceutical and biotechnology customers simplify workflows and accelerate the development of therapies.
That strategy is particularly relevant to India as pharmaceutical companies seek to improve productivity while maintaining quality.
The ability to offer integrated solutions could make laboratory technology providers more valuable partners to drugmakers.
AI Is Becoming Part of the Laboratory Revolution
Artificial intelligence is also becoming increasingly important in pharmaceutical research.
Thermo Fisher has been expanding its capabilities in AI-enabled research and clinical development, highlighting how digital technologies can help simplify complex workflows and accelerate drug development.
For Indian laboratories, the adoption of AI could create another wave of modernization.
As research becomes increasingly data-intensive, laboratories will need technologies capable of generating, analyzing and managing large amounts of information.
This could further increase demand for sophisticated laboratory infrastructure in India.
Why India Could Become a Strategic Hub
India offers several advantages for global life sciences companies.
The country has a large pharmaceutical manufacturing base, a growing biotechnology ecosystem, a substantial pool of scientific and technical talent and an expanding domestic healthcare market.
The combination creates an environment where demand for laboratory technology can grow alongside the broader life sciences industry.
For Thermo Fisher, this means India could become an increasingly important component of its long-term Asia-Pacific strategy.
The company is effectively positioning itself to grow alongside India’s transition from a manufacturing-focused pharmaceutical powerhouse toward a more innovation-driven life sciences economy.
Competition Will Also Increase
The opportunity in India is significant, but Thermo Fisher is not operating in an empty market.
Global laboratory equipment manufacturers, analytical technology companies and specialized life sciences providers are also looking to benefit from India’s research expansion.
As pharmaceutical companies increase their spending, competition for major contracts and partnerships is likely to intensify.
Thermo Fisher’s advantage lies in the breadth of its portfolio and its ability to provide solutions across multiple stages of the pharmaceutical value chain.
Maintaining that advantage will require continued investment in technology, local capabilities and customer support.
The Bigger Picture for India’s Pharma Industry
Thermo Fisher’s expansion is ultimately a reflection of a broader transformation within Indian pharmaceuticals.
The industry is moving toward higher-value activities, including drug discovery, biologics, biosimilars, advanced manufacturing and research-intensive therapies.
That transition requires a supporting ecosystem.
Laboratory equipment manufacturers, contract research organizations, technology providers and specialized service companies all have a role to play.
If India’s pharmaceutical sector continues moving up the innovation ladder, demand for sophisticated scientific infrastructure is likely to rise with it.
Thermo Fisher Scientific is stepping up investments in India as pharmaceutical and biotechnology companies increase their focus on innovation. The company expects its Indian customer base to grow by 15%-20% over the next five years, supported by stronger biopharma research and manufacturing activity.
India’s growing emphasis on biosimilars, biologics, advanced therapies and global-quality laboratories is creating a favorable environment for laboratory equipment and life sciences technology providers.
With more than 5,000 employees already in the country and plans to expand its workforce, Thermo Fisher is signaling that it sees India’s growth as a long-term opportunity rather than a short-term market trend.
The company’s expanding capabilities in AI-enabled research, clinical development and advanced manufacturing further strengthen its position as pharmaceutical innovation becomes more sophisticated.
For India, the growing presence of Thermo Fisher represents more than increased access to laboratory equipment. It reflects the country’s rising importance as a global center for pharmaceutical research, biotechnology and innovation.
